Triptorelin: Uses, Mechanism, and Side Effects

Men diagnosed with advanced prostate cancer often want to understand how hormone-based therapies fit into treatment before starting one. Triptorelin is one such option, and its approved use, mechanism, and safety reports are outlined below.

Key takeaways

• Triptorelin is a synthetic GnRH agonist approved under the brand name Trelstar.
• It is indicated for the treatment of advanced prostate cancer.
• More than 300 clinical trials have studied triptorelin across various conditions.
• The most frequently reported adverse events in FAERS include death, off label use, and needle-site issues.
• No boxed warning appears on the current label.

What Triptorelin Is

Triptorelin is a lab-made decapeptide designed to mimic gonadotropin releasing hormone (GnRH), a natural signaling hormone. Laboratory studies show it is far more potent than the body's own GnRH at triggering luteinizing hormone release from pituitary cells. This heightened activity is what allows it to influence hormone-driven conditions such as prostate cancer.

What Triptorelin Is Approved For

Triptorelin, marketed as Trelstar, is approved for the treatment of advanced prostate cancer. As a GnRH agonist, it works by altering the hormonal signals that can drive tumor growth in this setting. The current label does not carry a boxed warning.

What the Evidence Shows

Triptorelin has been studied in more than 300 registered clinical trials spanning oncology and reproductive health uses. One phase 3 trial, HOBOE, evaluated adjuvant triptorelin alongside tamoxifen, letrozole, or letrozole plus zoledronic acid in premenopausal breast cancer patients, though its status is listed as unknown. A separate phase 4 trial compared a flexible GnRH antagonist protocol against a flare-up GnRH agonist protocol in poor responders and has been completed.

Reported Side Effects

FAERS reports, which reflect submitted reports rather than confirmed incidence or causation, show death as the most frequently logged term (468 reports), followed by off label use (395) and needle-related administration issues (227). Other commonly reported events include disease progression and fatigue (211 each), dose omission issues (203), hot flushes (200), and drug ineffectiveness (190). These patterns likely reflect the seriousness of the underlying cancers treated and the injectable nature of the drug, rather than a specific safety signal on their own.